X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (483) 483
Newspaper Article (61) 61
Patent (16) 16
Conference Proceeding (7) 7
Book Chapter (5) 5
Magazine Article (3) 3
Dissertation (2) 2
Reference (2) 2
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (235) 235
life sciences & biomedicine (230) 230
heart failure (194) 194
humans (181) 181
cardiovascular system & cardiology (171) 171
cardiac & cardiovascular systems (164) 164
male (124) 124
female (123) 123
aged (100) 100
middle aged (99) 99
abridged index medicus (76) 76
heart failure - drug therapy (67) 67
cardiovascular (60) 60
heart failure - physiopathology (57) 57
mortality (57) 57
risk factors (56) 56
care and treatment (52) 52
treatment outcome (50) 50
prognosis (48) 48
hospitalization (41) 41
double-blind method (40) 40
analysis (39) 39
cardiac patients (35) 35
clinical trials (35) 35
drug therapy (33) 33
heart failure - mortality (32) 32
internal medicine (32) 32
clinical medicine (30) 30
patient outcomes (30) 30
stroke volume (30) 30
general & internal medicine (28) 28
klinisk medicin (28) 28
spironolactone (27) 27
cardiac and cardiovascular systems (26) 26
heart diseases (26) 26
kardiologi (26) 26
aged, 80 and over (25) 25
medicine, general & internal (25) 25
peripheral vascular disease (25) 25
stroke volume - physiology (25) 25
adult (24) 24
patients (24) 24
prospective studies (24) 24
research (24) 24
cardiology and cardiovascular medicine (23) 23
follow-up studies (23) 23
heart failure with preserved ejection fraction (23) 23
tetrazoles - therapeutic use (23) 23
angiotensin-converting enzyme inhibitors - therapeutic use (22) 22
cardiovascular diseases (22) 22
heart failure - therapy (22) 22
angiotensin (21) 21
angiotensin receptor antagonists - therapeutic use (21) 21
mineralocorticoid receptor antagonists - therapeutic use (21) 21
diabetes (20) 20
aminobutyrates - therapeutic use (19) 19
enalapril (19) 19
quality of life (19) 19
usage (19) 19
cardiology (18) 18
dosage and administration (18) 18
enalapril - therapeutic use (18) 18
heart failure - complications (18) 18
natriuretic peptides (18) 18
time factors (18) 18
heart attacks (17) 17
hypertension (17) 17
spironolactone - therapeutic use (17) 17
survival rate - trends (17) 17
blood pressure (16) 16
diabetes mellitus (16) 16
heart (16) 16
hospitalization - statistics & numerical data (16) 16
cardiovascular disease (15) 15
diuretics (15) 15
echocardiography (15) 15
health aspects (15) 15
heart failure - epidemiology (15) 15
kaplan-meier estimate (15) 15
retrospective studies (15) 15
surgery (15) 15
cardiac output (14) 14
clinical trial (14) 14
heart failure - diagnosis (14) 14
mechanical engineering (14) 14
myocardial infarction (14) 14
blasting (13) 13
cardiovascular diseases - mortality (13) 13
dose-response relationship, drug (13) 13
heart failure - blood (13) 13
heating (13) 13
lighting (13) 13
machines or engines for liquids (13) 13
morbidity (13) 13
natriuretic peptide, brain - blood (13) 13
neprilysin (13) 13
or a reactive propulsive thrust, not otherwise provided for (13) 13
producing mechanical power (13) 13
united states - epidemiology (13) 13
weapons (13) 13
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet (British edition), ISSN 0140-6736, 03/2016, Volume 387, Issue 10024, pp. 1178 - 1186
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 12/2016, Volume 68, Issue 22, pp. 2425 - 2436
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 11/2012, Volume 60, Issue 20, pp. 2082 - 2089
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2014, Volume 371, Issue 11, pp. 993 - 1004
The angiotensin receptor–neprilysin inhibitor LCZ696 was compared with the ACE inhibitor enalapril in patients with advanced heart failure. LCZ696 was superior... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Aminobutyrates - adverse effects | Hospitalization - statistics & numerical data | Male | Aminobutyrates - therapeutic use | Enalapril - therapeutic use | Enalapril - adverse effects | Heart Failure - drug therapy | Stroke Volume | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Neprilysin - antagonists & inhibitors | Female | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Angiotensin Receptor Antagonists - adverse effects | Heart Failure - mortality | Heart failure | Enalapril | Patient outcomes | Angiotensin | Enalaprilat | Dosage and administration | Research | Drug therapy | Enzymes | Statistical analysis | Mortality | Angioedema | Hypotension | Cough | Studies | Hyperkalemia | Death | Neprilysin | Heart diseases | Index Medicus | Abridged Index Medicus | MORTALITY | SURVIVAL | RANDOMIZED-TRIAL | RECEPTOR | Klinisk medicin | NEUTRAL ENDOPEPTIDASE INHIBITION | NATRIURETIC-PEPTIDE | Medicine | Clinical Medicine | CONVERTING ENZYME-INHIBITION | MORBIDITY | EJECTION FRACTION | General & Internal | DOUBLE-BLIND
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2014, Volume 370, Issue 15, pp. 1383 - 1392
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 1995 - 2008
In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients... 
NEPRILYSIN INHIBITION | OUTCOMES | COTRANSPORTER 2 INHIBITORS | MECHANISM | EMPAGLIFLOZIN | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Glycated Hemoglobin A - analysis | Humans | Middle Aged | Ventricular Dysfunction, Left - complications | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Heart Failure - complications | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Kaplan-Meier Estimate | Stroke Volume - drug effects | Combined Modality Therapy | Hospitalization | Heart Failure - drug therapy | Cardiovascular Agents - therapeutic use | Diabetes Mellitus, Type 2 - blood | Ventricular Dysfunction, Left - drug therapy | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Measurement | Heart failure | Dapagliflozin | Patient outcomes | Physiological aspects | Cardiac output | Drug therapy | Testing | Intravenous administration | Renal function | Clinical trials | Hypoglycemia | Evidence-based medicine | Clinical outcomes | Sodium | Hemoglobin | Patient safety | Diabetes | Diabetes mellitus (non-insulin dependent) | Heart diseases | Drug dosages | Ejection fraction | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article